Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Thursday 16 September, 2010

Lipoxen PLC

Lipoxen & Baxter Agreement Up

RNS Number : 7835S
Lipoxen PLC
16 September 2010

For Immediate Release


16 September 2010





- Lipoxen Receives US$2m License Fee Payment -

- Baxter Issued Warrants to Subscribe for up to US$2m Equity -

- Baxter Selects Lead Polymer Polysialic Acid (PSA)-Factor VIII Candidate -

- Baxter Granted Right to Appoint NED to Lipoxen's Board -


Lipoxen plc (AIM: LPX), ('Lipoxen' or 'the Company') a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces an important transaction with Baxter International Inc., ("Baxter") a global healthcare company and Lipoxen's third largest shareholder.




In August 2005, Lipoxen and Baxter signed a License Agreement with a potential value of up to US$75 million in cash milestones plus royalties.


The current Transaction has been concluded pursuant to both:


(a)  The signing of a License Amendment Agreement, and,

(b)  Baxter's selection of a lead PSA-FVIII candidate.  PSA-FVIII is a longer-acting form of a Factor VIII molecule using Lipoxen's PolyXen® drug delivery technology.


Pursuant to the foregoing:


(a)  Lipoxen will receive a US$2 million licence fee payment within 20 days of today's date, being an amount otherwise due at a later date in respect of an Investigational New Drug (IND) filing as per the original License Agreement of 2005, such current payment being offset against that IND fee, and,

(b)  Lipoxen issuing to Baxter warrant rights entitling Baxter, at their sole option to subscribe for up to US$2m of new equity in Lipoxen from the date authority to issue sufficient number of shares is available to 30 June 2015 at an Exercise Price being the Volume Weighted Average Price (VWAP) of Lipoxen's shares for the 5 trading days up to close of business on September 15th, 2010, being an Exercise Price of 9.02 pence.


With the selection of the lead candidate now completed and its progression into pre-clinical development, Lipoxen will continue to work with Baxter to achieve the remaining US$71 million in additional potential cash milestones payments due plus royalties.


Baxter has also has been granted the right to nominate a Non-Executive Director to Lipoxen's Board with such nomination to be made no later than 31 December 2010.


Commenting on the announcement, Scott Maguire, CEO said:


"The continued support from Baxter of Lipoxen is key to our efforts to commercialise our platform technologies. We are very pleased with the ongoing positive preclinical results for the lead PSA-Factor VIII molecule which we are working on with Baxter."


"As announced in June this year, through the investigational studies in process, Baxter is exploring other potential factor replacement therapies in the treatment of haemophilia A and B and for patients with inhibitors. We are delighted that our relationship with one of the world's leading biopharmaceutical companies continues to evolve and we look forward to leveraging the expertise and success of our Factor VIII for the new candidates under investigation.  The success of the Baxter partnership and its expansion to further molecules validates the Lipoxen business model where positive pre-clinical and clinical results lead to further partnering opportunities."



- Ends -


For further information, please contact:


Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång

Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Jessica Fontaine

Lisa Baderoon


 Mobile:    +44 7721 413496


About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:


1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA


Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 


Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs.


The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a £1.2 million placing in April 2010 which was led by the Company's management team.


Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website:

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t